<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ensysce Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/ensysce-biosciences-inc</link>
<description>Latest news and press releases for Ensysce Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ensysce-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835638178dffbe2df0ef474.webp</url>
<title>Ensysce Biosciences Inc</title>
<link>https://6ix.com/company/ensysce-biosciences-inc</link>
</image>
<item>
<title>Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-irb-approval-of-final-phase-of-pf614-mpar-102-clinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-irb-approval-of-final-phase-of-pf614-mpar-102-clinical-study</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)</description>
</item>
<item>
<title>Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-second-financing-from-2025-agreement-to-advance-breakthrough-pain-programs</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-second-financing-from-2025-agreement-to-advance-breakthrough-pain-programs</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire /</description>
</item>
<item>
<title>Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30,</description>
</item>
<item>
<title>Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-initiates-live-ask-me-anything-ama-session-highlighting-growth-and-future-plans-78</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-initiates-live-ask-me-anything-ama-session-highlighting-growth-and-future-plans-78</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN DIEGO,</description>
</item>
<item>
<title>Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-protection-with-mparr-technology-1</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-protection-with-mparr-technology-1</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), ...</description>
</item>
<item>
<title>Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology </title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-protection-with-mparr-technology</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-protection-with-mparr-technology</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS</description>
</item>
<item>
<title>Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-initiates-review-of-strategic-alternatives-to-enhance-shareholder-value</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-initiates-review-of-strategic-alternatives-to-enhance-shareholder-value</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA /</description>
</item>
<item>
<title>Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-invited-to-participate-in-upcoming-scientific-and-industry-events</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-invited-to-participate-in-upcoming-scientific-and-industry-events</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~ SAN DIEGO, CALIFORNIA</description>
</item>
<item>
<title>Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-provides-enrollment-pivotal-130000923</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-provides-enrollment-pivotal-130000923</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering ...</description>
</item>
<item>
<title>Ensysce Biosciences Expands Global Opioid Patent Portfolio</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-expands-global-opioid-130000056</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-expands-global-opioid-130000056</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>Ensysce Biosciences Expands Global Opioid Patent Portfolio </title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-expands-global-opioid-patent-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-expands-global-opioid-patent-portfolio</guid>
<pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
<description>~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 /</description>
</item>
<item>
<title>Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-eu-patent-130000975</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-eu-patent-130000975</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>Ensysce Biosciences Issues Annual Shareholder Letter</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-issues-annual-shareholder-130000525</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-issues-annual-shareholder-130000525</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch FDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale Up MPAR® Patent Protection Extended Through 2042 Up to $20 Million in Funding Secured to ...</description>
</item>
<item>
<title>Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-achieves-major-milestone-130000387</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-achieves-major-milestone-130000387</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company ...</description>
</item>
<item>
<title>Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-broader-patent-130000947</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-announces-broader-patent-130000947</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>~ New U.S. Patent Extends Protection Through 2042 ~ ~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR® ~ SAN DIEGO, CA / ACCESS Newswire / December 2, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...</description>
</item>
<item>
<title>Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-positive-fda-130000290</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-positive-fda-130000290</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation ...</description>
</item>
<item>
<title>Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach </title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-positive-fda-feedback-on-pf614-manufacturing-approach</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-receives-positive-fda-feedback-on-pf614-manufacturing-approach</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc.</description>
</item>
<item>
<title>Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-4-million-130500101</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-secures-4-million-130500101</guid>
<pubDate>Mon, 17 Nov 2025 13:05:00 GMT</pubDate>
<description>~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)("Ensysce" or the "Company"), ...</description>
</item>
<item>
<title>Ensysce Biosciences Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-reports-third-quarter-211500004</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-reports-third-quarter-211500004</guid>
<pubDate>Fri, 14 Nov 2025 21:15:00 GMT</pubDate>
<description>~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by Preferred Stock Financing ~ SAN DIEGO, CA / ACCESS ...</description>
</item>
<item>
<title>Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025</title>
<link>https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-releases-symposium-highlights-120000751</link>
<guid isPermaLink="true">https://6ix.com/company/ensysce-biosciences-inc/news/ensysce-biosciences-releases-symposium-highlights-120000751</guid>
<pubDate>Fri, 10 Oct 2025 12:00:00 GMT</pubDate>
<description>~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation ...</description>
</item>
</channel>
</rss>